title: Synthetic miR-145 mimic inhibits multiple myeloma cell growth in vitro and in vivo.
abstract: Multiple myeloma (MM) is a disease with an adverse outcome and new therapeutic strategies are required to combat this disease. It is well known that tumor‑suppressor microRNA (miRNA) acts as a new potential anticancer agent. Accumulating evidence showed that microRNA-145 (miR-145) is a candidate tumor suppressor miRNA. However, whether miR-145 is involved in the development and progression of MM reamins to be determined. In the present study, we investigated the therapeutic potential of synthetic miR-145 against human MM cells in vitro and in vivo. The results showed that miR-145 was reduced in MM tissues and cell lines. Enforced expression of miR-145 by transfection with miR-145 mimics inhibited cell proliferation, migration, and the invasion abilities of H929 cells. Furthermore, our results demonstrated that the enforced expression of miR-145 in H929 cells profoundly decreased the levels of p-AKT and p-PI3K, which may contribute to some extent to the inhibition of MM cell proliferation and survival. The enforced expression of miR-145 in a xenograft mouse model suppressed tumor growth. In conclusion, our findings suggested that miR-145 may act as a tumor suppressor and contributes to the progression of MM. Additionally, miR-145 mimics is a potential therapeutic agent for the treatment of MM.
authors.affiliation: School of Pharmaceutical Sciences, Jilin University, Jilin, P.R. China.
authors.forename: Qi
authors.initials: Q
authors.lastname: Zhang
authors.affiliation: School of Pharmaceutical Sciences, Jilin University, Jilin, P.R. China.
authors.forename: Weiqun
authors.initials: W
authors.lastname: Yan
authors.affiliation: First Hospital of Jilin University, Jilin, P.R. China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Bai
authors.affiliation: School of Pharmaceutical Sciences, Jilin University, Jilin, P.R. China.
authors.forename: Hao
authors.initials: H
authors.lastname: Xu
authors.affiliation: School of Pharmaceutical Sciences, Jilin University, Jilin, P.R. China.
authors.forename: Changhao
authors.initials: C
authors.lastname: Fu
authors.affiliation: Institute of Virology and AIDS Research, First Hospital of Jilin University, Jilin, P.R. China.
authors.forename: Wenwen
authors.initials: W
authors.lastname: Zheng
authors.affiliation: First Hospital of Jilin University, Jilin, P.R. China.
authors.forename: Yingqiao
authors.initials: Y
authors.lastname: Zhu
authors.affiliation: School of Pharmaceutical Sciences, Jilin University, Jilin, P.R. China.
authors.forename: Jie
authors.initials: J
authors.lastname: Ma
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000235:genetics; D002453:Cell Cycle / Q000187:drug effects / Q000235:genetics; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000235:genetics; D006801:Humans; D008297:Male; D016513:Mice, SCID; D035683:MicroRNAs / Q000097:blood / Q000138:chemical synthesis / Q000235:genetics / Q000494:pharmacology*; D018716:Molecular Mimicry; D009101:Multiple Myeloma / Q000235:genetics* / Q000378:metabolism / Q000473:pathology*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D034741:RNA, Small Interfering / Q000235:genetics / Q000494:pharmacology; D014162:Transfection; D023041:Xenograft Model Antitumor Assays
chemical_list: C541010:MIRN145 microRNA, human; D035683:MicroRNAs; D034741:RNA, Small Interfering; D019869:Phosphatidylinositol 3-Kinases; D051057:Proto-Oncogene Proteins c-akt